Decongestion in patients with heart failure by sacubitrill-valsartan

Decongestion in patients with heart failure by sacubitrill-valsartan - DRY-START trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043656

Enrollment

100

Registered

2021-03-18

Start date

2021-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure with congestion

Interventions

Sacvitrill-valsartan 12 month maximum dose if tolerant enarapril or valsartan 12 month maximum dose if tolerant

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who have acute decompensated heart failure with NT-pro BNP more than 200pg/ml(sinus), 600pg/ml(AF). The transthoracic echocardiography shows congestion and EF>40% at discharge.

Exclusion criteria

Exclusion criteria: EF<40% or TTE does not show congestion severe valvular disease congenital heart disease constrictive pericarditis systolic blood pressure<110mmHg eGFR<30ml/min/1.73m2 K>5.2mmol/L Patients who does not take ACE-I/ARB or who can not take them. life expectancy < 6 months due to non-cardiovascular diseases

Design outcomes

Primary

Measure	Time frame
The improvement of congestion evaluated by transthoracic echocardiography at 6 month	—

Secondary

Measure	Time frame
The improvement of congestion evaluated by transthoracic echocardiography at 12 month	—

Countries

Japan

Contacts

Public Contactyutaka matsuhiro

osaka rosai hospital cardiology

junnai-hisho@osakah.johas.go.jp072-252-3561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026